The treatment of solid tumors including colorectal cancer, non-small cell lung cancer, prostate cancer, and breast cancer, remains a challenge. Although chimeric antigen receptor (CAR) T-cell therapies have achieved success in treating hematologic cancers, these therapies show limited effectiveness against solid tumors. This project seeks to develop a novel approach targeting solid cancers using a Dual-action Antigen-presenting CAR γδ T-cell (DACART) therapy that combines the strengths of current advances in cancer vaccination. The team aims to leverage the advancement of four key technologies: CAR T-cell therapies, including successful therapies for blood cancers and novel strategies for solid tumors; dendritic cell (DC)-based cancer vaccines; techniques for engineering and expanding γδ T cells pioneered at Luminary Therapeutics; and efficient transposon-based cell engineering systems. The project aims to deliver a single, off-the-shelf, cost-effective cell therapy that effectively kills solid tumors while stimulating an endogenous antitumor immune response with low rate of relapse.